Passage Bio

Update in progress

PASG (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Passage Bio is a genetic medicines company focused on developing gene therapies for central nervous system diseases. Its programs include PBFT02 (progranulin/GRN for frontotemporal dementia due to progranulin deficiency), PBGM01 (GLB1/ß-galactosidase for infantile GM1), PBKR03 (Krabbe disease), PBML04 (metachromatic leukodystrophy), and PBAL05 (ALS), plus others for Huntington’s disease. It collaborates with UPenn’s Gene Therapy Program and Catalent, founded in 2017 and based in Philadelphia.

Company score

Sentiment: 0.04; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.01; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.01; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationUnited States
CEODr. William Chou M.D., Ph.D.
Founded2017
Employees24
Websitewww.passagebio.com

Identifiers

ISINUS7027121000
FIGIBBG00NBK4XF9
CUSIP702712100
CIK0001787297